News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
296,875 Results
Type
Article (18791)
Company Profile (328)
Press Release (277756)
Section
Business (86314)
Career Advice (240)
Deals (14302)
Drug Delivery (35)
Drug Development (58524)
Employer Resources (38)
FDA (6798)
Job Trends (6129)
News (161205)
Policy (12354)
Tag
Academia (1275)
Alliances (23689)
Alzheimer's disease (841)
Antibody-drug conjugate (ADC) (61)
Approvals (6771)
Artificial intelligence (77)
Bankruptcy (112)
Best Places to Work (5490)
Biotechnology (269)
Breast cancer (118)
Cancer (1064)
Cardiovascular disease (74)
Career advice (195)
CAR-T (90)
Cell therapy (249)
Clinical research (46221)
Collaboration (341)
Compensation (153)
COVID-19 (1869)
C-suite (81)
Cystic fibrosis (70)
Data (1108)
Diabetes (95)
Diagnostics (1561)
Earnings (31588)
Events (52418)
Executive appointments (265)
FDA (7232)
Funding (328)
Gene editing (65)
Gene therapy (176)
GLP-1 (327)
Government (1747)
Healthcare (7789)
Infectious disease (1944)
Inflammatory bowel disease (107)
IPO (7861)
Job creations (979)
Job search strategy (187)
Layoffs (214)
Legal (1560)
Lung cancer (169)
Lymphoma (76)
Manufacturing (97)
Medical device (2727)
Medtech (2728)
Mergers & acquisitions (6595)
Metabolic disorders (278)
Neuroscience (1101)
NextGen Class of 2024 (2273)
Non-profit (1135)
Northern California (1199)
Obesity (150)
Opinion (95)
Parkinson's disease (81)
Patents (74)
People (26912)
Phase I (16125)
Phase II (21263)
Phase III (13962)
Pipeline (408)
Postmarket research (1073)
Preclinical (6791)
Radiopharmaceuticals (208)
Rare diseases (216)
Real estate (1577)
Regulatory (9939)
Research institute (1308)
Southern California (1059)
Startups (2055)
United States (9706)
Vaccines (486)
Weight loss (89)
Date
Last 7 days (100)
Last 30 days (1085)
Last 365 days (22172)
2025 (55)
2024 (22684)
2023 (24970)
2022 (30103)
2021 (31799)
2020 (27182)
2019 (18453)
2018 (13496)
2017 (15592)
2016 (13582)
2015 (16246)
2014 (11737)
2013 (8491)
2012 (8557)
2011 (8517)
2010 (8206)
Location
Africa (208)
Asia (19223)
Australia (3410)
California (2720)
Canada (874)
China (230)
Colorado (107)
Connecticut (111)
Delaware (66)
Europe (41813)
Florida (305)
Georgia (83)
Illinois (171)
Indiana (106)
Maryland (388)
Massachusetts (2160)
Minnesota (105)
New Jersey (750)
New York (780)
North Carolina (442)
Northern California (1199)
Ohio (90)
Pennsylvania (513)
South America (257)
Southern California (1059)
Texas (313)
Washington State (280)
296,875 Results for "immune therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced the company will present Phase 1b interim data for IO-202 in patients with chronic myelomonocytic leukemia (CMML) at the 2024 European Hematology Association (EHA) Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
May 14, 2024
·
5 min read
Press Releases
Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) Annual Meeting
December 9, 2024
·
7 min read
Press Releases
Gnubiotics Secures Key Composition of Matter Patents for Obesity, Diabetes, and Immune-Related Diseases, Strengthening Its Glycopeptide Therapeutics Platform
October 8, 2024
·
1 min read
Drug Development
Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. announced the company will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia at the 2024 European Hematology Association Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
June 14, 2024
·
6 min read
Genetown
Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M.
April 3, 2024
·
4 min read
Defence’s AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that Defence’s Accum-002TM (“AccuTOX®") has different mode
July 1, 2024
·
5 min read
Press Releases
Immuneering Launches Pancreatic Cancer Advisory Board
December 20, 2024
·
5 min read
Press Releases
Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders
December 9, 2024
·
3 min read
Pharm Country
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
LAVA Therapeutics N.V. today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.
June 20, 2024
·
1 min read
Biotech Bay
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
February 21, 2024
·
6 min read
1 of 29,688
Next
